Ive trial styles and evaluation techniques for therapeutic studies of invasive mycoses. Clin Infect Dis 33: 95106. 9. Largent EA, Miller FG, Pearson SD Going off-label without having venturing off-course: proof and ethical off-label prescribing. Arch Intern Med 169: 17451747. ten. Sobel JD, Revankar SG Echinocandinsfirst-choice or first-line therapy for invasive candidiasis N Engl J Med 356: 25252526. 11. Fanaroff AA Fluconazole for the prevention of fungal infections: get ready, get set, caution. Pediatrics 117: 214215. 12. Lortholary O, Charlemagne A, Bastides F, Chevalier P, Datry A, et al. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France in the course of 19981999. J Antimicrob Chemother 54: 456464. 13. Gutierrez F, Wall PG, Cohen J An audit of your use of antifungal Fruquintinib chemical information agents. J Antimicrob Chemother 37: 175185. 14. Grasela TH, Goodwin SD, Pasko MT, Walawander CA, Raebel MA Use of antifungal therapy in hospitalized patients. I. Results prior to the advertising of fluconazole. Ann Pharmacother 28: 252260. 15. de With K, Steib-Bauert M, Knoth H, Dorje F, Strehl E, et al. Hospital use of systemic antifungal drugs. BMC Clin Pharmacol five: 1. 16. Prasad PA, Coffin SE, Leckerman KH, Walsh TJ, Zaoutis TE Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 27: 10831088. 17. Schneeweiss S, Seeger JD, Landon J, Walker AM Aprotinin during coronary-artery bypass grafting and risk of death. N Engl J Med 358: 771783. 18. Averill R, Goldfield N, Hughes J, Muldoon J, Gay J, et al. What Are APR-DRGs An Introduction to Severity of Illness and Risk of Mortality Adjustment Methodology. Salt Lake City, UT: 3M Well being Info Systems. 19. Wynn BO, Beckett M, Hillborne L, Scott M, Bahney B Evaluation of Severity-Adjusted DRG Systems: Interim 259869-55-1 Report. RAND Overall health working paper series Ready For the Centers for Medicare and Medicaid Solutions. 20. Schneeweiss S Developments in post-marketing comparative effectiveness study. Clin Pharmacol Ther 82: 143156. 21. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, et 
al. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting beneath circumstances of nonuniform impact. Am J Epidemiol 163: 262270. 22. Rosenbaum P, Rubin D The central part with the propensity score in observational research for causal effects. Biometrika 70: 4155. 23. Seeger JD, Williams PL, Walker AM An application of propensity score matching employing claims data. Pharmacoepidemiol Drug Saf 14: 465476. 24. Westreich D, Cole SR, Funk MJ, Brookhart MA, Sturmer T The function of the c-statistic in variable selection for propensity score models. Pharmacoepidemiol Drug Saf. 25. Sato T, Matsuyama Y Marginal structural models as a tool for standardization. Epidemiology 14: 680686. 26. Radley DC, Finkelstein SN, Stafford RS Off-label prescribing among office-based physicians. Arch Intern Med 166: 10211026. 27. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in sufferers with neutropenia and persistent fever. N Engl J Med 346: 225234. 28. Dai C, Stafford RS, Alexander GC National trends in cyclooxygenase-2 inhibitor use due to the fact market place release: nonselective diffusion of a selectively costeffective innovation. Arch Intern Med 165: 171177. 29. Berwick DM Disseminating innovations in wellness care. JAMA 289: 1969 1975. 30. Stafford RS Regulating of.Ive trial styles and evaluation approaches for therapeutic studies of invasive mycoses. Clin Infect Dis 
33: 95106. 9. Largent EA, Miller FG, Pearson SD Going off-label with out venturing off-course: proof and ethical off-label prescribing. Arch Intern Med 169: 17451747. 10. Sobel JD, Revankar SG Echinocandinsfirst-choice or first-line therapy for invasive candidiasis N Engl J Med 356: 25252526. 11. Fanaroff AA Fluconazole for the prevention of fungal infections: get ready, get set, caution. Pediatrics 117: 214215. 12. Lortholary O, Charlemagne A, Bastides F, Chevalier P, Datry A, et al. A multicentre pharmacoepidemiological study of therapeutic practices in invasive fungal infections in France in the course of 19981999. J Antimicrob Chemother 54: 456464. 13. Gutierrez F, Wall PG, Cohen J An audit from the use of antifungal agents. J Antimicrob Chemother 37: 175185. 14. Grasela TH, Goodwin SD, Pasko MT, Walawander CA, Raebel MA Use of antifungal therapy in hospitalized sufferers. I. Results prior to the marketing of fluconazole. Ann Pharmacother 28: 252260. 15. de With K, Steib-Bauert M, Knoth H, Dorje F, Strehl E, et al. Hospital use of systemic antifungal drugs. BMC Clin Pharmacol 5: 1. 16. Prasad PA, Coffin SE, Leckerman KH, Walsh TJ, Zaoutis TE Pediatric antifungal utilization: new drugs, new trends. Pediatr Infect Dis J 27: 10831088. 17. Schneeweiss S, Seeger JD, Landon J, Walker AM Aprotinin in the course of coronary-artery bypass grafting and threat of death. N Engl J Med 358: 771783. 18. Averill R, Goldfield N, Hughes J, Muldoon J, Gay J, et al. What Are APR-DRGs An Introduction to Severity of Illness and Threat of Mortality Adjustment Methodology. Salt Lake City, UT: 3M Well being Facts Systems. 19. Wynn BO, Beckett M, Hillborne L, Scott M, Bahney B Evaluation of Severity-Adjusted DRG Systems: Interim Report. RAND Wellness functioning paper series Prepared For the Centers for Medicare and Medicaid Services. 20. Schneeweiss S Developments in post-marketing comparative effectiveness investigation. Clin Pharmacol Ther 82: 143156. 21. Kurth T, Walker AM, Glynn RJ, Chan KA, Gaziano JM, et al. Outcomes of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting beneath circumstances of nonuniform effect. Am J Epidemiol 163: 262270. 22. Rosenbaum P, Rubin D The central part of your propensity score in observational studies for causal effects. Biometrika 70: 4155. 23. Seeger JD, Williams PL, Walker AM An application of propensity score matching applying claims data. Pharmacoepidemiol Drug Saf 14: 465476. 24. Westreich D, Cole SR, Funk MJ, Brookhart MA, Sturmer T The role from the c-statistic in variable choice for propensity score models. Pharmacoepidemiol Drug Saf. 25. Sato T, Matsuyama Y Marginal structural models as a tool for standardization. Epidemiology 14: 680686. 26. Radley DC, Finkelstein SN, Stafford RS Off-label prescribing among office-based physicians. Arch Intern Med 166: 10211026. 27. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in individuals with neutropenia and persistent fever. N Engl J Med 346: 225234. 28. Dai C, Stafford RS, Alexander GC National trends in cyclooxygenase-2 inhibitor use considering that market release: nonselective diffusion of a selectively costeffective innovation. Arch Intern Med 165: 171177. 29. Berwick DM Disseminating innovations in well being care. JAMA 289: 1969 1975. 30. Stafford RS Regulating of.
